Search

Search Results

• 

  34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo^1|2, Bruna Dalmasso³, Maria Chiara Scaini⁴, Laura Cendron⁵, Monica Rodolfo⁶, Ilaria Mattavelli⁷, Elena Tamborini⁸, Francesca Collina⁹, Gerardo Ferrara, Gabriele Madonna¹⁰, Carlo Cota¹¹, Elisa Melucci¹², Stefania Tommasi¹³, Martina Ubaldi¹⁴, Roberta Depenni¹⁵, Andrea Carugno¹⁶, Riccardo Marconcini¹⁷, Laura Orgiano¹⁸, Maurizio Lombardo¹⁹, Simona Sola²⁰, Cristina Pellegrini²¹, Francesca Castiglione²², Matteo Gasparotto^5|23, Alireza Jorkesh⁵, Stefania Pellegrini⁴, Edoardo Raposio¹, Andrea Boutros², Enrica Teresa Tanda², Michele Guida²⁵, Pietro Quaglino²⁶, Giuseppe Palmieri²⁷, Daniela Massi²², Paolo Antonio Ascierto¹⁰, Mario Mandalà*²⁸, Chiara Menin*⁴, Paola Ghiorzo*²⁴, Lorenza Pastorino*²⁴, for the Italian Melanoma Intergroup²⁹ | ¹Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; ²IRCCS Ospedale Policlinico San Martino, Genova; ³IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; ⁴Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; ⁵Department of Biology, University of Padua, Padua; ⁶Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁷Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁸Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁹Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; ¹⁰Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; ¹¹Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; ¹²Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; ¹³Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; ¹⁴Unit of Medical Oncology, University of Perugia; ¹⁵Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; ¹⁶Department of Medicine and Surgery, University of Insubria, Varese; ¹⁷Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; ¹⁸Department of Medical Oncology, University of Cagliari, Cagliari; ¹⁹Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; ²⁰Surgical Pathology, Galliera Hospital, Genoa; ²¹Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; ²²Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; ²³Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ²⁴Department of Internal Medicine and Medical Specialties, University of Genoa; ²⁵Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; ²⁶Dermatology Clinic, Department of Medical Sciences, University of Turin; ²⁷Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; ²⁸University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; ²⁹Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10776

  295
• 

  30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti^1|2, Giuseppe Agenziano³, Emi Dika^4|5, Emanuela Passoni⁶, Ketty Peris⁷, Pietro Quaglino⁸, Paola Queirolo⁹, Massimiliano Scalvenzi¹⁰, Iris Zalaudek¹¹, Luigi Lorini¹¹, Cristina Gurizzan¹, Monica Variolo^1|2, Paolo Bossi*^1|2, Carlo Resteghini*^1|2 | ¹Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; ²Department of Biomedical Sciences, Humanitas University, Rozzano ^MI; ³Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁴Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; ⁵Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; ⁶Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Dermatologic Clinic, University of Turin Medical School, Turin; ⁹Medical Oncology Unit; ¹⁰Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; ¹¹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10772

  312
• 

  25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo^1|2, Carlo Resteghini^1|2, Sara Farinatti^1|2, Andrea Alberti³, Valeria Tovazzi³, Paola Queirolo⁴, Maristella Saponara⁴, Giuseppe Argenziano⁵, Riccardo Marconcini⁶, Ketty Peris⁷, Paola Savoia⁸, Maria Chiara Tronconi¹, Iris Zalaudek⁹, Paolo Ascierto¹⁰, Francesco Spagnolo¹¹, Luigi Lorini¹, Cristina Gurizzan¹, Paolo Bossi^1|2 | ¹Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano ^MI; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; ³Medical Oncology Unit, ASST Spedali Civili, Brescia; ⁴Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; ⁵Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁶Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Department of Health Sciences, University of Eastern Piedmont, Novara; ⁹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; ¹⁰Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; ¹¹Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10767

  287
• 

  20 | How Covid-19 pandemic influenced the diagnosis of new primary melanoma: a retrospective, multicenter study by the Italian Society of Oncological Surgery Giuseppe Sciacca*^1|2, Luca Nespoli¹, Virginia Caliendo², Dario Piazzalunga³, Piero Rossi⁴, Marco Clementi⁵, Corrado Caracò⁶, Salvatore Asero⁷, Matteo Mascherini⁸, Franco De Cian⁸, Francesco Russano⁹, Paolo Del Fiore⁹, Sara Coppola¹⁰, Elisabetta Pennacchioli¹⁰, Pietro Gallina¹¹, Marzia Franzò¹², Marco Rastrelli^9|12 | ¹General and Emergency Surgery, School of Medicine and Surgery, Milano-Bicocca University, Fondazione IRCCS San Gerardo dei Tintori, Monza; ²Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; ³Unit of Surgery, Papa Giovanni XXIII Hospital, Bergamo; ⁴Dipartimento Di Scienze Chirurgiche, Università di Roma Tor Vergata, Policlinico Tor Vergata, Rome; ⁵General Surgical Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; ⁶Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori "Fondazione Pascale" IRCCS, Napoli; ⁷Soft Tissue U.O. Surgical Oncology-Soft Tissue Tumors, Dipartimento di Oncologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania; ⁸Department of Surgical Sciences and Integrated Diagnostic DISC, University of Genoa; ⁹Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; ¹⁰Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milano; ¹¹Directorate General, Veneto Institute of Oncology IOV-IRCCS, Padua; ¹²Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, AOPD Azienda Ospedale Università Padova, Padova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10762

  312
• 

  36 | Neoadjuvant strategy for locally advanced conjunctival melanoma: a single-center approach to eye preservation F. Rifaldi^1|2, M. Angi³, L. Giuseppe¹, F. Lanza³, A. Spagnoletti¹, J. Sergenti³, A. Indini¹, E. Mastrogiuseppe³, M. Del Vecchio¹, L. Di Guardo¹ | ¹Melanoma Medical Oncology Unit, Department of Medical Oncology ed Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ²Fondazione IRCCS Policlinico San Matteo, Pavia; ³Ocular Oncology Service, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10778

  355